117P Immune checkpoint inhibitors (ICI) in combination with chemotherapy as first-line (1L) treatment for non-small cell lung cancer (NSCLC): A pair-wise meta-analysis (MA)

ConclusionThe association of immunotherapy plus CH is a better treatment option for all patients in 1L NSCLC. Standard subgroups are the most benefited, except liver mx patients and EGFR/ALK+ especially benefited for the combination of an antiPD-L1 and an antiVEGF. Table:117P OS by subgroupsHR (CI 95%)Women0.51 [0.32-0.84]Men0.75 [0.64-0.87]<650.62 [0.46-0.84] ≥650.74 [0.63-0.87]PS 00.65 [0.49-0.88]PS 10.72 [0.60-0.87]Never smoker0.47 [0.26-0.85]Smoker0.71 [0.56-0.91]No liver mx0.61 [0.55-0.67]Liver mx0.69 [0.46-1.0]PD-L1 H0.66 [0.52-0.82]Legal entity responsible for the studyThe authors.FundingRoche Farma S.A.DisclosureF.J. Afonso-Afonso: Advisory / Consultancy: Roche; Advisory / Consultancy: Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Speaker Bureau / Expert testimony: Lilly; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: Janssen; Advisory / Consultancy, Travel / Accommodation / Expenses: IPSEN; Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer; Advisory / Consultancy: Takeda; Advisory / Consultancy: Sanofi. M. Amenedo Gancedo: Advisory / Consultancy: Clovis Oncology; Advisory / Consultancy: Tesaro; Speaker Bureau / Expert testimony: AstraZeneca; Speaker Bureau / Expert testimony: PharmaMar; Speaker Bureau / Expert testimony: Roche. M.C. Areses Manrique: Speaker Bureau / Expert testimony: R...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research